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Abstract  
Background: There is only limited information available about the effect of age on 
course of cognitive decline in patients with onset of Alzheimer's Disease (AD) over 
the age of 64 years.  
Objective: We compared the rate of, and factors affecting, cognitive decline in 
patients with AD aged <65 years (young-onset AD), 65-74 years (middle-onset AD), 
and ≥75 years (late-onset AD). 
Method: The study used longitudinal data from the Essex Memory Clinic which 
included a total of 305 participants; 56 had YOAD, 73 had MOAD, and 176 had 
LOAD. The rate of cognitive decline was measured using scores from the Mini 
Mental State Examination (MMSE), and the data were examined using multilevel 
models analysis. 
Results:  There was evidence of a difference in cognitive decline across the age 
groups with the YOAD group declining 2.8 MMSE points per year, those with MOAD 
declined 2.0 MMSE points per year and the LOAD group declined 1.4 MMSE points 
per year.  
Conclusions: Patients with LOAD have a better prognosis than YOAD and MOAD. 
However, even between the MOAD and LOAD groups, age is a significant predictor 
of cognitive decline, with older patients having a more benign course. 
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Introduction 
Alzheimer’s disease (AD) is conventionally defined as young- and late-onset AD 
(YOAD, LOAD) equating to age at onset <65 years and ≥65 years respectively. 
There is an abundance of literature looking at the relationship between age, both as 
a continuum and dichotomized, with the progression of cognitive impairment in AD. 
The majority of studies found a faster rate of cognitive decline in younger patients 
when looking either at age at which a diagnosis of AD is ascertained [1-12], or the 
age of onset, that is when symptoms first begin [13-14]. Some found no association 
between age of onset or diagnosis and rate of decline [15-20]. However, few studies 
have examined the effect of age on rate of decline within the LOAD group. As the 
prevalence of AD is increasing, and the UK population continues to age with a large 
AD cohort now aged over 65 years [21] there is a greater need for an understanding 
of the speed of decline of the disease and how age may affect this.   
 
In this study we looked at the age at which a diagnosis of AD was given and the rate 
of cognitive decline. Age at diagnosis is considered to be more reliable than age at 
onset which is dependent on patients/family members' historical accounts and 
therefore subject to bias. The age at which a diagnosis of AD was given was split 
into < 65 years and > 65 years in line with the diagnostic classification of AD into 
YOAD and LOAD respectively. We further stratified the over 65s in order to assess 
whether there was an effect of age on decline even within the over 65s. The LOAD 
group was subdivided into 65-74 years and ≥75 years. The 65-74 years old age 
group were defined as middle-onset AD (MOAD) and the ≥75 years old group were 
defined as late-onset AD (LOAD). The aim was to compare the rate of cognitive 
decline in patients with YOAD, MOAD and LOAD. We also sought to identify any 
additional factors that may influence the rate of decline including sex, years in 
education and vascular risk factors. 
 
 
Method 
Participants 
Patients were identified through the Essex Memory Clinic (EMC), a specialised 
memory assessment service that provides a detailed assessment of patients 
presenting with cognitive problems over the age of 40 following referrals from 
General Practitioners (GP) and allied health professionals. The results of the 
assessments are stored on the memory clinic's database following patient consent.  
If the outcome of an assessment reveals a diagnosis of dementia then patients are 
usually discharged from the EMC and subsequently followed up and reviewed locally 
by their respective Older Adult Mental Health team. Patients were given a consensus 
diagnosis following discussion between 2 Consultant Old Age Psychiatrists, a 
Clinical Psychologist and a Memory Clinic Nurse. Between March 1993 and July 
2015, 1827 patients were assessed (see figure 1). Of those, 612 had a diagnosis of 
AD at their most recent clinic visit. The inclusion criteria were patients aged 40 years 
or greater; meeting diagnostic criteria for possible or probable AD at their most 
recent visit (22); and at least 12 months follow up with repeated MMSE score (23) 
following the diagnosis of dementia. Patients were excluded if they had history of 
severe mental illness or substance misuse, or a change of diagnosis following 
discharge. Three hundred and five patients were included in the final analysis 
(YOAD n=56; MOAD n=73; LOAD n=176). 
 
Figure 1: study flowchart 
 
 
 
Procedure 
For each eligible patient demographic data, smoking (current and ex combined into 
one value versus never smoked), drinking habits, and vascular risk factors including 
history of myocardial infarction, hypertension, hypercholesteraemia, diabetes, and 
the Hachinski Ischaemic Score (HIS) were recorded [24]. We considered baseline 
MMSE score to be the score obtained at the time of AD diagnosis. Follow-up MMSE 
scores were taken at subsequent routine clinical assessments. The data were then 
transferred into SPSS (version 19) for analysis.   
 
Statistical analysis 
For baseline group comparisons, Mann-Whitney, Χ2 tests, and independent t tests 
were used where appropriate depending on the variable and distribution type.  In 
view of the hierarchical structure of our longitudinal data i.e. repeated measures of 
MMSE scores for each individual, a multilevel models analysis approach was 
adopted. This approach improves statistical power, as it accounts for within-person 
correlations over time, allows different numbers of assessments, can be used with 
datasets with missing data, and allows for varying time intervals between 
assessments [25]. 
 Multilevel models were used to assess associations between age at diagnosis and 
the rate of cognitive decline as measured by the MMSE. All assessments, including 
baseline, were taken into account. A random intercept and random slope were used 
for the analysis. The intercept represented the initial MMSE score, and the slope 
represented the rate of change in MMSE scores across time. The first model 
included terms for age at diagnosis; time; sex; years of education and the 
interactions between age at diagnosis and time; sex and time; and years of 
education and time, with the MMSE score as the dependent variable. Any non-
significant covariates were then removed from the model, and the variables smoking, 
alcohol use, and vascular risk factors were added to see if there was an association 
between them and initial MMSE status and/or rate of decline. In the final model 
reported here, only variables with a significant association with initial MMSE status 
and/or rate of decline were retained. From this model, the baseline MMSE and 
annual change in MMSE for patients with different age at diagnosis could be 
calculated. 
 
The continuous variable education was centred (mean subtracted from individuals’ 
scores) before the analysis. Age was trichotomized (<65 years, 65 to 74 years and 
>74 years). All analyses were conducted using SPSS version 21, with the 
significance level set at .05.   
 
Ethics 
The relevant Local Research Ethics Committee (NRES Committee South West - 
Cornwall and Plymouth and Exeter) gave ethical approval for the study.   
 Results 
Study Demographics 
Fifty six (18%) patients had YOAD, 73 (24%) had MOAD, and 176 (58%) had LOAD 
(see Tables 1 and 2). The mean age at diagnosis of persons with YOAD was 59.7 
years (range 48 to 64) and of MOAD 71.1 years (range 65 to 74). LOAD comprised a 
larger sample size of 176, mean age 80.2 years (range 75 to 92). There was no 
evidence of a difference in sex distribution between the three groups. Those with 
YOAD had an increased number of years in education compared to those with 
MOAD and LOAD (p<.01). There was no evidence of a difference between the 
duration of symptoms prior to diagnosis in the three groups. However, the first 
symptom of YOAD patients was more likely to be changes in mood such as anxiety 
and/or depression. There was also no evidence of a difference to our findings after 
adjusting for length of symptoms. The baseline severity (as measured using the 
MMSE and CAMCOG) of patients with YOAD was worse compared to those with 
MOAD and LOAD (p<.001). There was no difference in baseline severity between 
the MOAD and LOAD groups. The MOAD group had a greater number of follow ups 
compared to YOAD (p<.01). Of the possible covariates affecting cognitive decline the 
MOAD and LOAD groups had a higher rate of hypertension (p<.01); there were no 
differences in the other vascular measures, or smoking and alcohol habits. Fewer 
individuals with LOAD were taking the anti-dementia drug memantine in addition to 
their cholinesterase inhibitor (p<.01). 
 
Table 1 Baseline demographics and clinical characteristics between 
individuals with YOAD (<65 yrs), MOAD (65-74 yrs) and LOAD (>75 yrs) 
  
Table 2 Clinical characteristics (percent yes) 
 
 
 
Findings from the analysis 
The initial model included terms for age at diagnosis; time; sex; years of education 
and the interactions between age at diagnosis and time; sex and time; and years of 
education and time, with the MMSE score as the dependent variable. All covariates 
were significant at p<.05 with the exception of the interactions between time and 
years of education, and time and sex. The non-significant terms were dropped from 
the model and the following parameter estimates were obtained: for a patient with 
YOAD of average education and female sex, the initial MMSE status was 19.4 
points. At baseline the MOAD group had an MMSE score 4.8 points higher (p<.01); 
individuals with LOAD had an MMSE score that was 3.9 points higher (p<.01 versus 
YOAD); male sex was associated with an increase of 1.1 MMSE points (p<.05); and 
each extra year of education was associated with an increase of 0.3 MMSE points 
(p<.05). Regarding rate of change, YOAD patients declined by 0.23 MMSE points 
per month. Those with MOAD declined by 0.17 MMSE points per month (p<.05), and 
those with LOAD declined by 0.11 MMSE points per month (p<.01). Using estimated 
regression lines of MMSE score by time, the rate of decline in patients with YOAD 
was 2.7 MMSE points per year. At 48 months (in a prototypical YOAD patient with an 
initial MMSE of 19.4) the estimated MMSE score is 8.5. Patients with MOAD 
declined 2.0 points per year. At 48 months (in a prototypical MOAD patient with an 
initial MMSE of 24.3) the estimated MMSE score is 16.3. Patients with LOAD 
declined 1.3 points per year. At 48 months (in a prototypical LOAD patient with an 
initial MMSE of 23.4) the estimated MMSE score is 18.1. 
 
To the initial model, the variables smoking, alcohol use, and vascular risk factors 
were added to see if there was an association between them and initial MMSE status 
and/or rate of decline. Only diabetic status was significantly associated with initial 
MMSE status and no variables were associated with rate of decline. In the final 
model, all non-significant covariates were dropped. In the final model, the initial 
MMSE score of diabetic patients was 1.7 points higher (p<.05) than non-diabetic 
patients. All other parameter estimates were essentially unchanged from the initial 
model, including no change to the level of statistical significance. 
 
To supplement the analyses above, we directly compared initial MMSE status and 
rates of decline based on the final model for MOAD versus LOAD. In this model, the 
following parameter estimates were obtained: for a patient with MOAD of average 
education, female sex, and non-diabetic status the initial MMSE status was 24.0 
points. At baseline the LOAD group had an MMSE score 0.8 points lower (p=.14). 
Regarding rate of change, MOAD patients declined by 0.17 MMSE points per month.  
Those with LOAD declined by 0.11 MMSE points per month (p<.01; see Figure 2). 
 
Of the 305 cases studied, 54 only had 2 assessment time points. The results of 
patients with only 2 time points could be perceived as being less reliable. We 
therefore conducted a sensitivity analysis excluding cases with only 2 scores. The 
repeated analyses gave broadly similar results. However, additional years of 
education and diabetes were no longer associated with higher initial MMSE status. 
The rate of decline of early-onset cases decreased (from -0.23 to -0.20 MMSE points 
per month). This was still significantly different from zero. This slight reduction in rate 
of decline meant that there was no longer a significant difference in rate of decline 
between early- and middle-onset cases. However, there continued to be significant 
differences in rate of decline between early- and late-onset cases, and middle-onset 
and late-onset cases. 
 
Figure 2. Initial MMSE status (top) and rates of decline (bottom) for YOAD, MOAD 
and LOAD.  
 
 
 
Discussion 
Summary of main findings 
Patients with YOAD had a baseline MMSE score of 19.3. Patients with MOAD had a 
higher baseline MMSE score of 24.0, whereas those with LOAD had a score of 23.2 
It therefore did not follow a consistent trend that older patients presented with higher 
MMSE scores at baseline.  
 
In terms of rate of decline from the time of diagnosis individuals with YOAD declined 
0.23 MMSE points per month, those with MOAD declined 0.17 MMSE points per 
month, and those with LOAD declined 0.11 MMSE points per month. This equates to 
the YOAD individuals declining by 2.7 MMSE points per year, those aged 65 to 74 
declining by 2.0 points per year, and individuals with AD aged 75 and over declining 
by 1.3 points per year. 
 
The difference in baseline severity between those with YOAD and MOAD/LOAD may 
have accounted for a faster rate of decline in the YOAD group. Arguing against this, 
baseline severity was similar between those with MOAD and LOAD and yet the 
MOAD group declined faster than the LOAD group. 
 
Findings in the context of other literature 
The baseline MMSE for those with YOAD was significantly lower and the rate of 
decline faster compared to those with MOAD and LOAD. Accurate diagnosis of 
YOAD is challenging, particularly in the early stages, and as a consequence these 
patients tend to present late to memory services. Accordingly, they are more 
cognitively impaired at time of diagnosis, and as a result start antidementia therapy 
later than individuals with MOAD/LOAD. Yet interestingly in this sample patients with 
YOAD did not have a longer length of symptoms compared to those with LOAD. 
 
It could be argued that worse baseline severity of patients with YOAD accounts for 
their faster decline in the present sample. A systematic review looking at predictors 
of rate of decline concluded that more impaired patients declined faster, although the 
authors also acknowledged considerable heterogeneity amongst findings [26]. 
 
Yet interestingly in our study, whilst patients with YOAD had lower baseline MMSE 
scores and a faster rate of cognitive decline than those aged >65 years, there was a 
different pattern within the >65 years age group. The initial MMSE score of patients 
with MOAD did not significantly differ from that of patients with LOAD, but the MOAD 
patients declined more quickly. Therefore, whilst greater baseline severity may have 
contributed to increased rate of decline in the YOAD groups, this cannot be said for 
the differences in progression between MOAD and LOAD. This suggests that even 
within patients aged over 65 at diagnosis, age at diagnosis is a significant predictor 
of decline. Furthermore, in a meta-analysis of 10 AD clinical trials there was no 
difference in baseline MMSE across any of the age at diagnosis groups (range 48 to 
105 years), and yet the older patients declined more slowly. Therefore, in wider 
research the overall association between age at diagnosis and rate of decline 
appears to hold across all age groups, regardless of baseline severity [27]. 
 
The different rates of decline in AD depending on age at diagnosis may be 
connected to the observation that age-associated neuropathologies are not mutually 
exclusive. It is likely that there are interactions of different pathological processes or 
proteins that seem to aggravate each other [28]. Neuropathological studies suggest 
older adults are more likely to have simultaneous presence of multiple pathologies in 
the brain which may accelerate disease progression [28-30]. However from our 
sample of older patients and similar to other studies [2, 27], we found older adults 
had a slower rate of decline. A possible explanation for this is that younger 
individuals have a more “pure” and greater degree of AD pathology, whereas the 
“older” brain often has mixed neuropathologies [29]. Younger onset of AD is 
associated with greater grey matter atrophy, increased glucose hypometabolism and 
greater tau deposition measured using neuroimaging [31]; neuropathologically more 
severe senile plaques, neurofibrillary tangles and synapse loss [8]; as well as greater 
deficits in the neurochemical acetylcholine and other neurotransmitters such as 
adrenaline [32]. One large neuropathological study found that, while AD and other 
neurodegenerative pathologies were associated with progressive cognitive decline, 
some types of vascular pathology did impair cognition but the effect was stable over 
time [33]. In our study the MOAD and LOAD groups had a higher rate of 
hypertension compared to the YOAD group, and there was a difference in the HIS 
score between the LOAD and YOAD groups suggesting the possible addition of 
vascular pathology in older patients. In this study, therefore it is likely that the typical 
LOAD patient had more cerebrovascular disease (CVD) than YOAD patients. 
However the effects of mixed pathologies on clinical progression in AD remains an 
area of uncertainty, and there is a need for further studies to combine clinical and 
neuropathological data in particular to ascertain which pathologies are contributing to 
cognitive baselines, decline and trajectories [30]. 
 
 
Methodological considerations  
The study included a large sample of patients with AD, and there was a higher rate 
of inclusion of patients with YOAD compared to similar studies. There was also a 
substantial length of follow-up for all and a clear effect of age at diagnosis on the rate 
of cognitive decline was shown. Multilevel modelling is statistically powerful as it 
allows for repeated measurement of outcomes (MMSE) which can vary in number 
and interval between patients. All observations, including baseline, were a part of our 
analysis, but in view of the longitudinal nature of the study only patients with at least 
12 months follow up with repeated MMSE score were included. 
 
The limitations to this study are that there were no post-mortem data available, nor 
biomarkers to add weight to the clinical diagnosis, and therefore some patients may 
have had an alternative diagnosis to AD. There are also possible confounding 
factors which have not been accounted for including APOE genotype, concomitant 
medications and effectiveness of cholinesterase inhibitor medications such as agent 
and dose. Additionally, our longitudinal measure of cognition, the MMSE, has 
limitations. A previous study found that the measure of the rate of changes in MMSE 
scores were not as reliable when observations were separated by less than 36 
months [34]. Furthermore, our data by nature reflects patients who returned to 
services for follow-up assessment, and therefore may not generalize to patients who 
are seen only once in clinic. However all patients included in the analysis were 
assessed in a uniform manner against stringent diagnostic criteria.   
 
A further limitation to consider is using 'age at diagnosis' of AD as opposed to 'age at 
onset'. This may have introduced bias into the results as some patients may present 
later to memory services. Also, as discussed earlier, the diagnosis of YOAD in the 
early stages can be challenging which may result in these patients presenting later to 
memory services. Subsequently, they are more cognitively impaired at the time of 
diagnosis, and MMSE rate of change tends to accelerate for people with lower 
scores. It is therefore possible that age and the severity of cognitive impairment at 
diagnosis both influence the rate of decline in AD. 
 
Clinical and research implications 
It is important for clinicians to have an understanding of demographic variables 
affecting the course of cognitive decline in those with AD so that they can relay to 
patients and their carers the likely progression and help them to plan and prepare for 
the future. In the research setting, when recruiting patients it is important to consider 
the age at onset of participants, since our and other studies have shown there is a 
reliable association between age at onset and rate of decline. Researchers testing 
interventions should consider the use of stratified randomisation based on age at 
diagnosis rather than age at study entry. 
 
Conclusion 
In conclusion, we found there was some evidence of slower decline at older ages. 
The greater baseline severity of the YOAD is unlikely to have fully accounted for the 
increased rate of decline versus those >65. The MOAD group declined faster than 
the LOAD group despite the two groups having similar baseline MMSE scores. 
Therefore even within patients aged over 65 at diagnosis, age is a significant 
predictor of decline. Other than age there were no independent variables in our data 
analysis significantly associated with the rate of decline in AD.   
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Table 1 Baseline demographics and clinical characteristics between 
individuals with YOAD (<65 yrs), MOAD (65-74 yrs) and LOAD (>75 yrs) 
 
Young-
onset 
(n=56) 
Middle-onset 
(n=73) 
Late-onset 
(n=176) 
p Value 
Sex, (%) male 45 38 45 .62 
Years in 
education, mean 
(SD) 
11.3 (2.1) a 10.6 (1.7) b 10.4 (1.6) a, b <.01 
Age at diagnosis 
(years), mean 
(SD) 
59.7 (3.2) 71.1 (2.6) 80.2 (3.7) n/a 
HIS 0.7 (1.1) a 1.0 (1.6) 1.0 (1.1) a <.05 
First symptom 
(%) 
Memory=75 
Affective=23 
Language=2 
a,b 
Memory=97 
Affective=3 
Language=0 
a 
Memory=99 
Affective=1 
Language=0 
b 
<.01 
Length of 
symptoms (SD) 
31.4 (26.0) 37.9 (26.5)  30.6 (23.9) .06 
MMSE at 
diagnosis, mean 
(SD) 
18.4 (6.1) a, 
b 
23.2 (3.3) a 23.0 (3.2) b <.01 
CAMCOG at 
diagnosis, mean 
(SD) 
64.0 (18.6) 
a, b 
78.8 (9.4) a 76.5 (10.0) b <.01 
Number of 
follow-ups, mean 
(SD) 
4.5 (2.6) a 
6.0 (3.3) a 
 
 
4.8 (2.5) <.01 
Length follow-up, 
median (range) in 
months 
41.0 (4-122) 
a 
48.0 (12-210) a, 
b 
36.5 (4-149) b <.05 
Pairs of letters a, b, c indicate pairs that differ at p<.05. 3-way continuous tests are 
Kruskal-Wallis, 2-way continuous tests are Mann-Whitney. Sex variable p value from 
Chi-Square test. First symptom variable p value from Fisher’s exact test. 
 
 
 
  
 Table 2 Clinical characteristics (percent yes) 
 Young-onset 
(n=56) 
Middle-onset 
(n=73) 
Late-onset 
(n=176) 
P Value 
Hypertension 20 a, b 51 a 51 b <.01 
Diabetes 9 14 8 .37 
Hypercholesterolemi
a 
18 30 31 .15 
History MI 4 10 10 .30 
Smoker 39 40 42 .83 
Alcohol 70 67 63 .73 
ACHEI 93 88 90 .42 
Memantine 9 a 7 b 1 a, b <.01 
Pairs of letters a and b indicate pairs that differ at p<0.05. All comparisons are Chi 
Square. 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Initial MMSE status (top) and rates of decline (bottom) for YOAD, 
MOAD and LOAD.  
 
